CN112516003A - Use of cyclodextrin for inhibiting growth of oral bacteria - Google Patents
Use of cyclodextrin for inhibiting growth of oral bacteria Download PDFInfo
- Publication number
- CN112516003A CN112516003A CN202011506465.6A CN202011506465A CN112516003A CN 112516003 A CN112516003 A CN 112516003A CN 202011506465 A CN202011506465 A CN 202011506465A CN 112516003 A CN112516003 A CN 112516003A
- Authority
- CN
- China
- Prior art keywords
- cyclodextrin
- oral
- bacteria
- composition
- inhibiting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920000858 Cyclodextrin Polymers 0.000 title claims abstract description 64
- 241000894006 Bacteria Species 0.000 title claims abstract description 59
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title claims abstract description 46
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 26
- 239000000203 mixture Substances 0.000 claims abstract description 33
- 210000000214 mouth Anatomy 0.000 claims abstract description 25
- 239000004480 active ingredient Substances 0.000 claims abstract description 22
- 238000004519 manufacturing process Methods 0.000 claims abstract description 11
- 208000024693 gingival disease Diseases 0.000 claims abstract description 10
- 230000003628 erosive effect Effects 0.000 claims abstract description 7
- 239000002324 mouth wash Substances 0.000 claims description 21
- 229940051866 mouthwash Drugs 0.000 claims description 17
- 239000000284 extract Substances 0.000 claims description 13
- 239000004615 ingredient Substances 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 6
- -1 circulation improver Substances 0.000 claims description 6
- 239000000796 flavoring agent Substances 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 239000002738 chelating agent Substances 0.000 claims description 5
- 235000013355 food flavoring agent Nutrition 0.000 claims description 5
- 239000003906 humectant Substances 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- 239000002562 thickening agent Substances 0.000 claims description 5
- 241000186046 Actinomyces Species 0.000 claims description 4
- 239000001116 FEMA 4028 Substances 0.000 claims description 4
- 241000606790 Haemophilus Species 0.000 claims description 4
- 241000191940 Staphylococcus Species 0.000 claims description 4
- 241000194017 Streptococcus Species 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 4
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 4
- 229960004853 betadex Drugs 0.000 claims description 4
- 239000004075 cariostatic agent Substances 0.000 claims description 4
- 208000007565 gingivitis Diseases 0.000 claims description 4
- 239000006041 probiotic Substances 0.000 claims description 4
- 235000018291 probiotics Nutrition 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 241000195940 Bryophyta Species 0.000 claims description 3
- 241000588722 Escherichia Species 0.000 claims description 3
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 3
- 230000002421 anti-septic effect Effects 0.000 claims description 3
- 239000007938 effervescent tablet Substances 0.000 claims description 3
- 239000006260 foam Substances 0.000 claims description 3
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 3
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims description 3
- 239000007937 lozenge Substances 0.000 claims description 3
- 235000011929 mousse Nutrition 0.000 claims description 3
- 201000001245 periodontitis Diseases 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 230000000529 probiotic effect Effects 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000000606 toothpaste Substances 0.000 claims description 3
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 2
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 239000006172 buffering agent Substances 0.000 claims description 2
- 210000004195 gingiva Anatomy 0.000 claims description 2
- 210000002379 periodontal ligament Anatomy 0.000 claims description 2
- 229940034610 toothpaste Drugs 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 230000032770 biofilm formation Effects 0.000 claims 1
- 230000002439 hemostatic effect Effects 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 8
- 239000003899 bactericide agent Substances 0.000 abstract description 7
- 229940097362 cyclodextrins Drugs 0.000 abstract description 7
- 206010059866 Drug resistance Diseases 0.000 abstract description 4
- 230000007794 irritation Effects 0.000 abstract description 4
- 239000003960 organic solvent Substances 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 16
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 16
- 230000000694 effects Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 230000001580 bacterial effect Effects 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 10
- 230000009471 action Effects 0.000 description 9
- 230000003385 bacteriostatic effect Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 241000588747 Klebsiella pneumoniae Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 5
- 229920000742 Cotton Polymers 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 229940030225 antihemorrhagics Drugs 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000013065 commercial product Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000002874 hemostatic agent Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000007721 medicinal effect Effects 0.000 description 3
- 229940041616 menthol Drugs 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000002688 persistence Effects 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 238000001223 reverse osmosis Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- 208000002064 Dental Plaque Diseases 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 240000004670 Glycyrrhiza echinata Species 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 208000025157 Oral disease Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 2
- UJNOLBSYLSYIBM-WISYIIOYSA-N [(1r,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl] (2r)-2-hydroxypropanoate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)[C@@H](C)O UJNOLBSYLSYIBM-WISYIIOYSA-N 0.000 description 2
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000002925 dental caries Diseases 0.000 description 2
- 239000003975 dentin desensitizing agent Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940094522 laponite Drugs 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- XCOBTUNSZUJCDH-UHFFFAOYSA-B lithium magnesium sodium silicate Chemical compound [Li+].[Li+].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 XCOBTUNSZUJCDH-UHFFFAOYSA-B 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 208000030194 mouth disease Diseases 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 235000019477 peppermint oil Nutrition 0.000 description 2
- 230000003239 periodontal effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011775 sodium fluoride Substances 0.000 description 2
- 235000013024 sodium fluoride Nutrition 0.000 description 2
- 229960000414 sodium fluoride Drugs 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- ANOBYBYXJXCGBS-UHFFFAOYSA-L stannous fluoride Chemical compound F[Sn]F ANOBYBYXJXCGBS-UHFFFAOYSA-L 0.000 description 2
- 229960002799 stannous fluoride Drugs 0.000 description 2
- DHEQXMRUPNDRPG-UHFFFAOYSA-N strontium nitrate Chemical compound [Sr+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O DHEQXMRUPNDRPG-UHFFFAOYSA-N 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 229960003500 triclosan Drugs 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- NHJUPBDCSOGIKX-QMWFWAMKSA-N 1-O-(D-glucosyl)glycerol Chemical compound OCC(O)COC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NHJUPBDCSOGIKX-QMWFWAMKSA-N 0.000 description 1
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 1
- WXNZTHHGJRFXKQ-UHFFFAOYSA-N 4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1 WXNZTHHGJRFXKQ-UHFFFAOYSA-N 0.000 description 1
- DDFHBQSCUXNBSA-UHFFFAOYSA-N 5-(5-carboxythiophen-2-yl)thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C1=CC=C(C(O)=O)S1 DDFHBQSCUXNBSA-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 241000565319 Butea monosperma Species 0.000 description 1
- NEZONWMXZKDMKF-UHFFFAOYSA-N C.I. Natural Red 20 Chemical compound C1=CC(O)=C2C(=O)C(C(O)CC=C(C)C)=CC(=O)C2=C1O NEZONWMXZKDMKF-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229940090898 Desensitizer Drugs 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 235000017048 Garcinia mangostana Nutrition 0.000 description 1
- 240000006053 Garcinia mangostana Species 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 240000000950 Hippophae rhamnoides Species 0.000 description 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 1
- 241000218195 Lauraceae Species 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 235000011030 Lithospermum officinale Nutrition 0.000 description 1
- 240000004035 Lithospermum officinale Species 0.000 description 1
- 241000218378 Magnolia Species 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000123069 Ocyurus chrysurus Species 0.000 description 1
- 235000011203 Origanum Nutrition 0.000 description 1
- 240000000783 Origanum majorana Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 241000605861 Prevotella Species 0.000 description 1
- 235000002226 Ranunculus ficaria Nutrition 0.000 description 1
- 244000081426 Ranunculus ficaria Species 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000015125 Sterculia urens Nutrition 0.000 description 1
- 240000001058 Sterculia urens Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 description 1
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 description 1
- 235000007746 carvacrol Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 239000001279 citrus aurantifolia swingle expressed oil Substances 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000035597 cooling sensation Effects 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical class C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000019820 disodium diphosphate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- GYQBBRRVRKFJRG-UHFFFAOYSA-L disodium pyrophosphate Chemical compound [Na+].[Na+].OP([O-])(=O)OP(O)([O-])=O GYQBBRRVRKFJRG-UHFFFAOYSA-L 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- WQXNXVUDBPYKBA-YFKPBYRVSA-N ectoine Chemical compound CC1=[NH+][C@H](C([O-])=O)CCN1 WQXNXVUDBPYKBA-YFKPBYRVSA-N 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940070818 glycyrrhizate Drugs 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 229940087603 grape seed extract Drugs 0.000 description 1
- 239000010651 grapefruit oil Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960002163 hydrogen peroxide Drugs 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- ZVVSSOQAYNYNPP-UHFFFAOYSA-N olaflur Chemical compound F.F.CCCCCCCCCCCCCCCCCCN(CCO)CCCN(CCO)CCO ZVVSSOQAYNYNPP-UHFFFAOYSA-N 0.000 description 1
- 229960001245 olaflur Drugs 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- 239000010670 sage oil Substances 0.000 description 1
- 239000010672 sassafras oil Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229910001631 strontium chloride Inorganic materials 0.000 description 1
- 229940013553 strontium chloride Drugs 0.000 description 1
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 description 1
- 229940026236 strontium nitrate Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- XROWMBWRMNHXMF-UHFFFAOYSA-J titanium tetrafluoride Chemical compound [F-].[F-].[F-].[F-].[Ti+4] XROWMBWRMNHXMF-UHFFFAOYSA-J 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 1
- 235000019801 trisodium phosphate Nutrition 0.000 description 1
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000001717 vitis vinifera seed extract Substances 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000011746 zinc citrate Substances 0.000 description 1
- 235000006076 zinc citrate Nutrition 0.000 description 1
- 229940068475 zinc citrate Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/738—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Abstract
The present invention discloses the use of a cyclodextrin for the manufacture of a composition for inhibiting the growth of oral bacteria, wherein the composition comprises an active ingredient which is maintained in the oral cavity for a specific period of time to inhibit oral bacteria. Can inhibit the growth of bacteria and avoid the generation of drug resistance of bacteria without using bactericides and organic solvents which have high irritation on body cells. The present disclosure provides the use of cyclodextrins for the manufacture of compositions for inhibiting plaque, erosion, calculus or ameliorating gum disease on a dental surface.
Description
Technical Field
The invention belongs to the technical field of application of cyclodextrin to oral care, and particularly relates to application of cyclodextrin to inhibition of oral bacterial growth.
Background
The oral cavity is a complex and complete microecosystem, and a proper environment and conditions are provided for the growth and propagation of various microorganisms through a biofilm formed by the interaction among microorganisms, microorganism metabolites and oral cavity secretion. Studies have indicated that the occurrence of several oral diseases, such as caries, calculus, periodontal disease, gingivitis, etc., are associated with the proliferation of harmful bacteria that grow on the oral biofilm. If the growth of harmful bacteria in the oral cavity can be inhibited in a large amount, oral diseases can be prevented and improved.
At present, the control of harmful bacteria in the oral cavity mainly depends on methods such as broad-spectrum chemical bactericides, antibiotics and the like. However, since broad-spectrum chemical bactericides and antibiotics are highly irritant, long-term use of the bactericides and antibiotics can cause massive death of oral bacteria or cause drug resistance of the bacteria, cause imbalance of oral flora and even cause variation of oral cells, and cause other diseases. In addition, since broad-spectrum chemical antiseptics or antibiotics often require an organic solution (e.g., alcohol) as a solvent, there is a risk of damaging the oral mucosa when used.
Therefore, how to provide a mild and safe oral bacteriostatic agent with bacteriostatic effect and without drug resistance is a problem to be solved.
Disclosure of Invention
The present invention provides the use of a cyclodextrin for the manufacture of a composition for inhibiting the growth of oral bacteria.
According to an embodiment of the invention, the composition comprises an active ingredient which is maintained in the oral cavity for a specific time to inhibit oral bacteria, wherein the active ingredient comprises a cyclodextrin.
According to a preferred embodiment of the invention, the cyclodextrin is the only active ingredient inhibiting bacteria.
According to an embodiment of the invention, the oral bacteria comprise streptococcus, haemophilus, actinomyces, raviolella, escherichia coli, staphylococcus or a combination thereof. For example, it may be Klebsiella pneumoniae, Staphylococcus aureus or Escherichia coli.
According to an embodiment of the invention, the cyclodextrin comprises at least one of an a-cyclodextrin, a β -cyclodextrin, a γ -cyclodextrin, a δ -cyclodextrin, or a derivative of each.
According to an embodiment of the invention, the composition is an oral care product.
According to an embodiment of the invention, the cyclodextrin is present in the composition in a weight percentage of between 0.1% and 1.5%.
According to an embodiment of the invention, the oral care implement is selected from the group consisting of a mouthwash, toothpaste, tooth gel, tooth powder, gel, mousse, foam, mouth spray, lozenge, or effervescent tablet.
According to an embodiment of the present invention, the ingredients of the oral care product further comprise a surfactant, an antiseptic, an anti-inflammatory agent, a hemostatic agent, a desensitizing agent, an anti-caries agent, an antioxidant, a circulation-improving agent, a vitamin, a probiotic extract, or a combination thereof.
According to embodiments of the present invention, the ingredients of the oral care implement further comprise a thickening agent, a chelating agent, a buffer, a humectant, a flavoring agent, or a combination thereof.
According to an embodiment of the invention, inhibiting oral bacteria comprises inhibiting bacteria in the oral cavity from forming a biofilm.
The present invention also provides the use of a cyclodextrin for the manufacture of a composition for inhibiting plaque, acid erosion, calculus or a combination of the foregoing on a dental surface.
According to embodiments of the present invention, the composition is maintained in the oral cavity for a specific time to inhibit plaque, acid erosion, calculus, or a combination of the foregoing on the tooth surface.
The present invention also provides a use of cyclodextrin for manufacturing a composition for improving gum disease, wherein the composition is maintained in an oral cavity for a specific time to improve gum disease, wherein the gum disease comprises gingivitis or periodontitis including gingiva, periodontal ligament, alveolar bone and cementum.
Advantageous effects
The cyclodextrin provided by the invention is used for inhibiting the growth of oral bacteria, and the growth of the bacteria can be inhibited without using bactericides (such as quaternary ammonium salt and the like) with high irritation to body cells and organic solvents. Moreover, the taste is mild, and the use will of the user can be improved. In addition, the cyclodextrin has the property of dissolving aid, and the medical effect or physiological activity corresponding to other functional active ingredients can be synergistically enhanced by increasing the upper limit of the dissolution of other functional active ingredients.
Drawings
FIG. 1 is a graph comparing the change of the number of bacteria per unit volume of hydroxypropyl-beta-cyclodextrin in the first example against Klebsiella pneumoniae at different action times (1 minute and 6 hours) and at different action concentrations (0.1%, 1%, 10%).
FIG. 2 is a graph comparing the change of the number of bacteria per unit volume of hydroxypropyl-beta-cyclodextrin against Staphylococcus aureus in example one at different action times (1 minute and 6 hours) and at different action concentrations (0.1%, 1%, 10%).
FIG. 3 is a graph comparing the change of the number of bacteria per unit volume of hydroxypropyl-cyclodextrin in the first example against E.coli at different action times (1 minute and 6 hours) and at different action concentrations (0.1%, 1%, 10%).
Fig. 4 is a graph comparing the bacteriostatic ability of hydroxypropyl-beta-cyclodextrin with different weight percentages after hydroxypropyl-beta-cyclodextrin acts on oral bacteria for 1 minute in example one.
Fig. 5 is a graph comparing the bacteriostatic ability of hydroxypropyl-beta-cyclodextrin with different weight percentages after 6 hours of the effect of hydroxypropyl-beta-cyclodextrin on oral bacteria in example one.
Detailed Description
The composition and its use of the present invention will be described in further detail with reference to specific examples. It is to be understood that the following examples are only illustrative and explanatory of the present invention and should not be construed as limiting the scope of the present invention. All the technologies realized based on the above-mentioned contents of the present invention are covered in the protection scope of the present invention.
Unless otherwise indicated, the raw materials and reagents used in the following examples are all commercially available products or can be prepared by known methods.
As used herein, the terms "a" and "an" can refer broadly to a single or a plurality of items, unless the context specifically states otherwise. It will be further understood that the terms "comprises," "comprising," "includes," "including" and similar terms, when used herein, specify the presence of stated features, regions, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of other features, regions, integers, steps, operations, elements, components, and/or groups thereof.
Although the present invention is illustrated below as a series of acts or steps, the order in which the acts or steps are presented should not be construed as a limitation of the present invention. For example, certain operations or steps may be performed in a different order and/or concurrently with other steps. Moreover, not all operations, steps and/or features may be required to implement an embodiment of the present invention. Moreover, each operation or step described herein may include several sub-steps or actions.
As used herein, "oral care product" means a composition that may include oral care, oral hygiene or oral appearance for its intended use, or a method of use for its intended purpose may include administration to the oral cavity. In some embodiments, the oral care composition is not swallowed, but remains in the oral cavity for a period of time sufficient for the desired use.
As used herein, "biofilm" means the various microbial communities on tooth or periodontal surfaces embedded in a polymer matrix of bacterial and salivary origin, the formation of which involves earlier bacterial colonization and interaction between this film. Subsequently, the second colony attaches to the already attached early colony (co-aggregate) and this process allows the formation of a mature biofilm. Inhibiting biofilm growth can prevent and reduce bacterial reattachment to the tooth surface or periodontal surface.
For example, dental plaque is a biofilm of many oral bacteria that adheres to the surface of teeth in a three-dimensional structure, the complex structure making it possible to include bacteria of varying sensitivity to oxygen that grow, develop and die embedded in a polymeric matrix consisting of polysaccharides, proteins and minerals. Some bacteria in dental plaque, which produce metabolites to etch tooth enamel or gum, cause tooth decay or sensitive teeth, or cause plaque to deposit on teeth, causing symptoms such as calculus …, are the main causative factors of gum disease (e.g., gingivitis or periodontitis).
In some embodiments of the present disclosure, there is provided a use of Cyclodextrin (CD) for inhibiting oral bacteria, comprising maintaining the cyclodextrin in the oral cavity for a specified time. In some embodiments, the oral bacteria include, but are not limited to, Streptococcus (Streptococcus), Haemophilus (Haemophilus), Actinomyces (Actinomyces), reivorax (Prevotella), Escherichia (Escherichia), or Staphylococcus (Staphylococcus). In some embodiments, the specified time comprises 0.5 to 10 minutes. In one embodiment, the inhibition of oral bacterial growth is achieved for a period of at least 0.5 minutes, 1 minute, 5 minutes, 10 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, or any interval of the foregoing. In some embodiments, inhibiting oral bacteria can comprise inhibiting the bacteria in the oral cavity from forming a biofilm.
The cyclodextrin is an unsaturated six-membered heterocyclic compound, is harmless to human bodies, has mild and nonirritant mouthfeel, has the amphoteric molecular characteristics of a hydrophobic inner cavity and a hydrophilic shell, can be used as an inclusion body in the inner cavity, contains various hydrophobic molecules, and has the applications of assisting dissolution, fixing molecules, conveying medicines, deodorizing and the like. It is noteworthy that some embodiments in the context of the present invention take advantage of the amphoteric structural properties of cyclodextrins, which are first used to inhibit the growth of oral bacteria, to coat metabolites produced by oral bacteria and avoid the formation of bacterial biofilms. In some embodiments, the cyclodextrin includes one or more of alpha-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, delta-cyclodextrin, or a derivative thereof, and different cyclodextrins have different hydrophobic molecule coating abilities and water solubility, and suitable cyclodextrins can be selected according to requirements. For example, hydroxypropyl- β -cyclodextrin (HP- β -CD) is modified from β -cyclodextrin, is inexpensive and widely available, has excellent water solubility, can be directly prepared as a mouthwash from water, is low in cost and highly convenient to use.
In some embodiments, the composition may be included in an oral care implement. In one embodiment, the cyclodextrin is present in the oral care implement at a weight percentage of 0.1% to 1.5%, e.g., 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, or any of the foregoing. When the concentration of cyclodextrin is too high or too low, the effect of inhibiting the growth of bacteria cannot be achieved, when the concentration is too high, part of bacteria (such as Klebsiella pneumoniae) can grow, and when the concentration is too low, the effect is not good.
In some embodiments, the oral care implement is selected from the group consisting of mouthwashes, toothpastes, tooth gels, tooth powders, gels, mousses, foams, mouth sprays, lozenges, or effervescent tablets. In one embodiment, the oral care composition can be used in non-human mammals such as pets (e.g., dogs and cats), and humans. In one embodiment, the oral care composition is suitable for use in humans only.
In some embodiments, the ingredients of the oral care product further comprise a surfactant, a functional active ingredient, or both. In one embodiment, the weight percentage of the surfactant in the oral care implement is from 0.01% to 30%, such as 0.01%, 0.1%, 1%, 5%, 10%, 15%, 30%, or any of the foregoing. In one embodiment, the weight percentage of the functional active ingredient in the oral care implement is from 0.01 to 10%, such as 0.01%, 0.1%, 1%, 5%, 10%, or any of the foregoing.
In one embodiment, the surfactant is selected from one or more of an anionic surfactant, a cationic surfactant, a nonionic surfactant, or an amphoteric surfactant.
Functional active ingredients generally refer to ingredients having a medical effect or physiological activity, such as bactericides, anti-inflammatory agents, hemostatic agents, desensitizing agents, anticaries agents, antioxidants, circulation-improving agents, vitamins, probiotics, or probiotic extracts.
In one embodiment, the antimicrobial agent comprises a cationic antimicrobial agent, benzoate, iodine, monochlorophenol, triclosan and zinc citrate, hydrogen peroxide, halogenated diphenyl ether (e.g., triclosan), vanilla extract and essential oils (e.g., rosemary extract, tea extract, magnolia extract, thymol, menthol, eucalyptol, geraniol, carvacrol, citral, hinokitiol, catechol, methyl salicylate, epigallocatechin gallate, epigallocatechin, gallic acid, meswak (miswak) extract, sea buckthorn extract) or combinations thereof.
In one embodiment, the anti-inflammatory agent comprises an extract of licorice (e.g., flavonoids in licorice (e.g., dipotassium glycyrrhizate, ammoniated glycyrrhizate, or glycyrrhetinic acid), an anti-inflammatory hormone (e.g., glucocorticoid), an extract of butea frondosa, red peony root, figwort root, gromwell root, madder root, cortex moutan, or a combination thereof.
In one embodiment, the hemostatic agent comprises tranexamic acid.
In one embodiment, the desensitizer comprises one or more of urea, strontium nitrate, strontium chloride, potassium citrate, stannous fluoride, potassium chloride, grape seed extract, mangosteen extract, apple extract.
In one embodiment, the anti-caries agent includes fluorides such as stannous fluoride, sodium fluoride, potassium fluoride, sodium monofluorophosphate, sodium fluorosilicate, ammonium fluorosilicate, amine fluoride, ammonium fluoride, titanium fluoride, hexafluorosulfate, or combinations thereof.
In one embodiment, the antioxidant comprises vitamins, antioxidant active ingredients in animal and plant extracts, or both.
In one embodiment, the circulation-improving agent comprises vitamin E and its derivatives, ectoin, a plant extract, or a combination thereof.
It is worth mentioning that cyclodextrin, when present in an oral care product, can also act as a co-solvent, for example, to raise the upper solubility limit of other functional active ingredients, and to raise the maximum content of the functional active ingredients due to limited solubility. That is, cyclodextrins, in addition to inhibiting oral bacterial growth, also have a synergistic effect of simultaneously increasing the upper limit of efficacy of other functional active ingredients.
In some embodiments, the ingredients of the oral care product further comprise excipients (also called excipients) mainly for enhancing the effect of the functional active ingredients or promoting dissolution and absorption in the final form to enhance the effect of the active ingredients. Such as thickeners, chelating agents, buffers, humectants, flavoring agents, or combinations thereof. In one embodiment, the adjuvant is present in the oral care implement in an amount of 0.02 to 20% by weight, for example 0.02%, 0.1%, 1%, 5%, 10%, 15%, 20% or any of the foregoing.
Thickeners are substances that provide a desired consistency or stability, enhancing the performance of the oral care product. In one embodiment, thickeners such as hyaluronic acid, polyvinylpyrrolidone, cellulose, oligosaccharides, glucosyl glycerol, carboxyvinyl polymers, carrageenan, hydroxyethyl cellulose (HEC), natural and synthetic clays (such as magnesium aluminum silicate (VEEGUM) and laponite (e.g., laponite)), water-soluble salts of cellulose ethers (such as sodium carboxymethyl cellulose (CMC) and sodium carboxymethyl hydroxyethyl cellulose), natural gums (such as karaya, xanthan, acacia and tragacanth), colloidal magnesium aluminum silicate, silicones (such as finely powdered silicone), polyvinyl pyrrolidone, carbowax, fatty acids and salts thereof, or combinations thereof.
Chelating agents refer to compounds that can form stable water-soluble complexes with alkaline earth and heavy metal ions. In one embodiment, the chelating agent comprises, for example, edetate.
The buffering agent can adjust the pH of the oral care composition to, for example, a range of about pH 4.0 to about pH 8.0. In one embodiment, the buffer comprises sodium chloride or sodium fluoride, sodium bicarbonate, sodium phosphate (e.g., sodium dihydrogen phosphate (NaH)2PO4) Disodium hydrogen phosphate (Na)2HPO4) Trisodium phosphate (Na)3PO4) Sodium hydroxide, sodium carbonate, sodium acid pyrophosphate, citric acid, sodium citrate, and mixtures or combinations thereof.
Humectants refer to ingredients that avoid hardening when the oral care product is exposed to air. In one embodiment, a humectant is such as glycerin, sorbitol, propylene glycol, or a combination thereof.
Flavoring agents refer to substances that modify the mouth feel or taste of an oral care product. In one embodiment, flavoring agents can provide a cooling taste, such as mint and extracts thereof (e.g., menthol, peppermint oil), borneol (crystals from extractions of branches or leaves of Lauraceae plants), essential oils, and one or more of various flavoring aldehydes, esters (e.g., menthyl lactate), or alcohols. The essential oil can include peppermint oil, oil of wintergreen, sassafras oil, clove oil, sage oil, eucalyptus oil, marjoram oil, cinnamon oil, lemon oil, lime oil, grapefruit oil, willow oil, or combinations thereof. In one embodiment, the flavor is present in the oral care implement at a weight percentage of 0.005 to 2%, e.g., 0.005%, 0.01%, 0.1%, 0.15%, 0.2%, or any of the foregoing.
In some embodiments of the present disclosure, there is also provided a use of a cyclodextrin for the manufacture of a composition for inhibiting plaque, acid erosion, calculus, or a combination thereof, on a dental surface, wherein the composition is maintained in the oral cavity for a specific time to inhibit plaque, acid erosion, calculus, or a combination thereof, on the dental surface.
In some embodiments of the present disclosure, there is also provided a use of cyclodextrin for the manufacture of a composition for ameliorating gingival disease, wherein the composition is maintained in the oral cavity for a specific time to ameliorate gingival disease.
To further illustrate the use of cyclodextrins provided in various embodiments of the present invention to inhibit the growth of oral bacteria, the following is performed. It should be noted that the following examples are provided for illustrative purposes only and do not limit the present invention.
EXAMPLE I bacteriostatic test with Cyclodextrin
To test the inhibitory effect of cyclodextrins on oral bacteria, hydroxypropyl- β -cyclodextrin (0.1%, 1%, and 10% by weight) was mixed with Klebsiella pneumoniae (Klebsiella pneumoniae), Staphylococcus aureus (Staphyloccusaureus), and Escherichia coli (Escherichia coli) for specific time periods (1 minute and 6 hours) at different action concentrations, wherein the initial reaction concentration of each group of bacteria was 1 × 105cfu/mL, the number of colonies per unit volume of each group of bacteria was examined, and the results are plotted in FIGS. 1 to 3.
The results show that the group of 0.1% and 1% hydroxypropyl- β -cyclodextrin inhibited bacterial growth for either 1 minute or 6 hours. However, when the concentration is increased to 10%, the growth of the bacteria of the genus Klebsiella pneumoniae is promoted (47 × 10)5cfu/mL). That is, cyclodextrin is controlled to have an appropriate concentration to have an effect of inhibiting the growth of oral bacteria.
Further, the bacteriostatic power (%) of hydroxypropyl- β -cyclodextrin was defined as (bacterial amount of control group-bacterial amount of experimental group)/bacterial amount of control group, and the bacteriostatic power of 0.1% and 1% hydroxypropyl- β -cyclodextrin for each group of bacteria in fig. 1 to 3 was converted and plotted as fig. 4 and 5.
The results show that, in general, 1% hydroxypropyl-beta-cyclodextrin has better bacteriostatic ability, and the effect of simultaneously inhibiting the growth of three bacteria can be achieved within 1 minute. In addition, the bacteriostasis capacity to part of bacteria is improved along with the improvement of action time.
EXAMPLE two Cyclodextrin cleaning test
To test the cleaning effect of removing oral bacteria using a mouthwash containing hydroxypropyl- β -cyclodextrin, the bacteria solution was decanted after culturing the escherichia coli and mold/yeast mixtures separately using culture tubes for two days. Then, the tube wall was coated with a cotton swab, and a test piece (JNC SKNeofilm) standardized by the food method was usedTWMicroorganism quick detection tablet) for detecting the bacterial amount of cotton stick, wherein the Escherichia coli is detected by JNC Escherichia coli/Escherichia coli group test tablet (model #6635), the mould/yeast is detected by JNC yeast and mould test tablet (model #6640), and the initial bacterial amount of each group is 1x104cfu/mL. Then, a mouth wash was poured, and after shaking for 1 minute, the mouth wash was poured out, wherein the mouth wash contained three groups, each consisting of 1% aqueous solution of cyclodextrin at 25 ℃, reverse osmosis hot water at 65 ℃, and reverse osmosis normal temperature water at 25 ℃. Then, the tube wall was coated with the cotton swab again, the bacteria stained with the cotton swab were cultured for two days, and the amount of bacteria was calculated again using the test piece standardized by the food method, and the results are shown in table 1 below.
Table 1 comparative cleaning effect of cyclodextrin
The results in table 1 show that when an aqueous cyclodextrin solution is used as a mouthwash and the rinsing step is performed to simulate a mouth rinsing process, the aqueous cyclodextrin solution can achieve better bacteria and fungi removal and better cleaning effects than reverse osmosis water at 65 ℃ or 25 ℃.
EXAMPLE III mouthwash containing Cyclodextrin
To further confirm the actual use of the oral care product containing cyclodextrin, after the cyclodextrin was added with natural ingredients to prepare a concentrated mouthwash (the formulation contained 47.5% hydroxypropyl- β -cyclodextrin, 3.5% propylene glycol, 3.5% natural menthol, 1.0% menthyl lactate, 4.5% dipotassium glycyrrhizate, and water in parts by mass), stability and a questionnaire on use after dilution were investigated, respectively. When the concentrated mouthwash in example 3 is applied to the oral cavity, the concentrated mouthwash in example three needs to be diluted by water, and the concentrated mouthwash in example three is the mouthwash with 1% -3% of hydroxypropyl-beta-cyclodextrin.
1. Stability testing of concentrated mouthwashes
The concentrated mouthwash is placed at room temperature/12 months, 30 ℃/12 months and 45 ℃/6 months respectively, and then the appearance, smell, content and microbial production (whether fungi, mold, escherichia coli, pseudomonas aeruginosa (pseudomonas aeruginosa) or staphylococcus aureus is produced or not are detected, wherein the lower detection limit is 10cfu/g) are observed, and the results are shown in table 2.
TABLE 2 stability results of concentrated mouthwashes
The results show that the concentrated mouthwash can be stored at 45 ℃ for at least 6 months without deterioration and at room temperature and 30 ℃ for at least 12 months without deterioration.
2. Use feeling questionnaire survey of concentrated mouthwash
The subjects were asked to take 13 subjects, after rinsing with water, to use the test groups (the concentrated rinse from example three was diluted with water to a 1% hydroxypropyl- β -cyclodextrin rinse) and the commercial product (lusterlin antibacterial rinse) rinse, respectively, followed by filling out the user experience questionnaire. The subject's perceived intensity was scored from 1 to 5. For example, a stimulation score of 5 indicates high stimulation, a score of 1 indicates low stimulation; the cooling persistence degree is 5, which indicates long persistence time, and the score is 1, which indicates short persistence time; the refreshing feeling was rated 5, indicating high refreshing property, and rated 1, indicating low refreshing property. Next, whether the average value of the scores of the commercial product and the test product was significantly different was examined by statistical analysis. Finally, the questionnaire results were collated into tables 3 to 5.
TABLE 3 sensory evaluation of concentrated mouthwashes
TABLE 4 feeling of use score of concentrated mouthwash-Cool durability
TABLE 5 feeling of use score of concentrated mouthwash-fresh feeling
The results show that the commercial product and the test product have a significant difference in irritation, while the cooling duration and the cooling sensation are not significantly different. The taste of the test products in the examples of the invention is milder and has no burden compared with the commercially available products.
The cyclodextrin provided by some embodiments of the present disclosure is used for inhibiting the growth of oral bacteria, and the cyclodextrin is firstly used as a functional active ingredient for oral health care, can inhibit the growth of bacteria without using a bactericide which is conventionally highly irritating to body cells, avoids the formation of a biofilm and the risk of drug resistance of bacteria, has an excellent effect of removing bacteria and fungi, and can achieve a shelf life of at least one year without using a preservative. In addition, the cyclodextrin is mild in taste and soluble in water, so that the prepared oral care product has no irritation to oral mucosa, and the use will of a user can be improved.
In addition, the cyclodextrin and other functional active ingredients have synergistic effect, and the cyclodextrin can increase the solubility upper limit of the functional active ingredients by utilizing the solubilizing assisting property of amphiphilic molecules on the self structure, so that the medical effect or the physiological activity corresponding to the functional active ingredients is further improved.
The embodiments of the present invention have been described above. However, the present invention is not limited to the above embodiment. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (9)
1. Use of a cyclodextrin in the manufacture of a composition for inhibiting the growth of oral bacteria, wherein the composition comprises an active ingredient which is maintained in the oral cavity for a specified time to inhibit oral bacteria, wherein the active ingredient comprises a cyclodextrin.
2. Use according to claim 1, characterized in that cyclodextrin is the only active ingredient inhibiting bacteria.
Preferably, the oral bacteria comprise streptococcus, haemophilus, actinomyces, raviolella, escherichia, staphylococcus, or combinations thereof.
3. The use of claim 1, wherein the cyclodextrin comprises one or more of alpha-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, delta-cyclodextrin, or a derivative thereof.
4. The use according to claim 1, wherein the composition is an oral care product.
5. The use according to claim 4, wherein the cyclodextrin is present in the oral care product in an amount of from 0.1% to 1.5% by weight.
6. The use according to claim 4, wherein the oral care product comprises a mouthwash, toothpaste, tooth gel, tooth powder, gel, mousse, foam, mouth spray, lozenge, or effervescent tablet.
Preferably, the oral care composition further comprises a surfactant, antiseptic, anti-inflammatory, hemostatic, desensitizing, anticaries agent, antioxidant, circulation improver, vitamin, probiotic extract, or combinations thereof.
Preferably, the ingredients of the oral care implement further comprise a thickening agent, a chelating agent, a buffering agent, a humectant, a flavoring agent, or a combination thereof.
7. The use of claim 4, wherein inhibiting oral bacteria comprises inhibiting biofilm formation by bacteria in the oral cavity.
8. Use of a cyclodextrin in the manufacture of a composition for inhibiting plaque, acid erosion, calculus, or a combination thereof, on a dental surface, wherein the composition is maintained in the oral cavity for a specified period of time to inhibit plaque, acid erosion, calculus, or a combination thereof on the dental surface.
9. Use of a cyclodextrin in the manufacture of a composition for ameliorating gum disease, wherein the composition is maintained in the oral cavity for a specified period of time to ameliorate gum disease, wherein the gum disease comprises gingivitis or periodontitis including gingiva, periodontal ligament, alveolar bone, and cementum.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011506465.6A CN112516003A (en) | 2020-12-18 | 2020-12-18 | Use of cyclodextrin for inhibiting growth of oral bacteria |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011506465.6A CN112516003A (en) | 2020-12-18 | 2020-12-18 | Use of cyclodextrin for inhibiting growth of oral bacteria |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112516003A true CN112516003A (en) | 2021-03-19 |
Family
ID=75001869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011506465.6A Pending CN112516003A (en) | 2020-12-18 | 2020-12-18 | Use of cyclodextrin for inhibiting growth of oral bacteria |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112516003A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113975185A (en) * | 2021-09-27 | 2022-01-28 | 深圳芳新悦享品牌管理有限公司 | Toothpaste containing bioactive glass particles and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101151037A (en) * | 2005-01-28 | 2008-03-26 | 平纳克尔医药股份有限公司 | Beta-cyclodextrin derivatives as antibacterial agents |
| US20150315298A1 (en) * | 2014-04-02 | 2015-11-05 | University Of South Carolina | Cyclodextrin Functionalized Nanoparticles for Quenching Bacterial Communications |
| CN107551038A (en) * | 2017-10-11 | 2018-01-09 | 南京仙草堂生物科技有限公司 | A kind of medical mouthwash and preparation method thereof |
| CN111000754A (en) * | 2019-12-31 | 2020-04-14 | 合肥赛为智慧医疗有限公司 | Mouthwash for balancing oral flora and preparation method thereof |
| CN111053718A (en) * | 2019-12-31 | 2020-04-24 | 合肥赛为智慧医疗有限公司 | Mouthwash with function of resisting helicobacter pylori in oral cavity |
-
2020
- 2020-12-18 CN CN202011506465.6A patent/CN112516003A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101151037A (en) * | 2005-01-28 | 2008-03-26 | 平纳克尔医药股份有限公司 | Beta-cyclodextrin derivatives as antibacterial agents |
| US20150315298A1 (en) * | 2014-04-02 | 2015-11-05 | University Of South Carolina | Cyclodextrin Functionalized Nanoparticles for Quenching Bacterial Communications |
| CN107551038A (en) * | 2017-10-11 | 2018-01-09 | 南京仙草堂生物科技有限公司 | A kind of medical mouthwash and preparation method thereof |
| CN111000754A (en) * | 2019-12-31 | 2020-04-14 | 合肥赛为智慧医疗有限公司 | Mouthwash for balancing oral flora and preparation method thereof |
| CN111053718A (en) * | 2019-12-31 | 2020-04-24 | 合肥赛为智慧医疗有限公司 | Mouthwash with function of resisting helicobacter pylori in oral cavity |
Non-Patent Citations (1)
| Title |
|---|
| 吕厚东: "《全国高等医药院校医学检验技术专业十三五规划教材 临床微生物学检验技术》", 31 January 2020 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113975185A (en) * | 2021-09-27 | 2022-01-28 | 深圳芳新悦享品牌管理有限公司 | Toothpaste containing bioactive glass particles and preparation method thereof |
| CN113975185B (en) * | 2021-09-27 | 2023-06-23 | 深圳小爱大爱科技有限责任公司 | Toothpaste containing bioactive glass particles and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7592025B2 (en) | Vehicles for oral care with magnolia bark extract | |
| EP0420630B1 (en) | Antiplaque oral compositions | |
| AU603203B2 (en) | Disinfecting compositions and methods therefor | |
| CN101222909B (en) | Breath freshening and oral cleansing product with magnolia bark extract in combination with surface active agents | |
| JP5452221B2 (en) | Combinations for obtaining oral compositions, their production and use | |
| HRP950385A2 (en) | Antiseptic dentifrice | |
| US20020156130A1 (en) | Multi-functional dental composition | |
| MX2007007705A (en) | Antibacterial and anti-inflammatory oral care composition. | |
| US20070237806A1 (en) | Multi-functional dental composition | |
| JP2000512660A (en) | Antimicrobial agents for oral hygiene products | |
| JP2008143825A (en) | Tooth paste composition | |
| JP2008303188A (en) | Candida biofilm eliminating agent | |
| JP2010018544A (en) | Antimicrobial agent, composition for oral cavity and denture cleanser | |
| JP2012144480A (en) | Oral cavity composition | |
| EP4044996B1 (en) | Oral care composition | |
| CN112516003A (en) | Use of cyclodextrin for inhibiting growth of oral bacteria | |
| JP5205618B2 (en) | Antibacterial agent | |
| TWI774079B (en) | Use of cyclodextrin for manufacturing a composition for inhibiting growth of oral bacteria | |
| JP2002234825A (en) | Composition for oral cavity application | |
| JP2003246717A (en) | Composition for oral cavity | |
| JP5631175B2 (en) | Oral composition | |
| CN109512683B (en) | Povidone-iodine composition and preparation method and application thereof | |
| CN111050747B (en) | Dentifrice composition | |
| JPH0495020A (en) | Enzyme inhibitor | |
| JP3022047B2 (en) | Oral composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210319 |
|
| RJ01 | Rejection of invention patent application after publication |